Compound tracker
5-MeO-DMT.
A source-backed research page for trial rows and update notes connected to this compound or investigational product. The page is generated from the Notion tracker and should be read as a living research map, not a medical conclusion.
15 trial rows 1 update rows Latest checked: May 12, 2026 All trials Claim boundary
Trial registration, company topline, CNPV/rolling-review status, recruitment status, public-dashboard data, or review literature do not equal approval, label, reimbursement, access, safety, or efficacy. Related update rows are shown only when they include visible Last checked text and an explicit Claim boundary.
Backlinks
This page links out to registry/source records, the global trial tracker, the updates feed, and matching wiki dossiers when available.
Phase 1 / Phase 1/2 / Phase 2
Phases tracked
Completed / Not yet recruiting / Recruiting
Statuses seen
Trial rows
NCT07540494 Phase 1 Not yet recruiting updated Apr 14, 2026
- Condition
- Healthy Adult
- Sponsor / institution
- GH Research Ireland Limited
- Start date
- Apr 1, 2026
Tracker note / source boundary
ClinicalTrials.gov v2 verification on 2026-04-24 | Overall status: NOT_YET_RECRUITING | Exact phase: PHASE1 | Lead sponsor: GH Research Ireland Limited | Conditions: Healthy Adult | Interventions: DRUG: 5 Methoxy N,N Dimethyltryptamine; DEVICE: GH001 Aerosol Delivery System | Registry start date type: ESTIMATED (2026-04).
NCT07444788 Phase 1 Recruiting updated Feb 24, 2026
- Condition
- Healthy Participants
- Sponsor / institution
- University Hospital, Basel, Switzerland
- Start date
- Mar 31, 2026
Tracker note / source boundary
ClinicalTrials.gov v2 verification on 2026-04-24 | Overall status: RECRUITING | Exact phase: PHASE1 | Lead sponsor: University Hospital, Basel, Switzerland | Conditions: 5-methoxy-dimethyltryptamine (5-MeO-DMT) | Interventions: DRUG: 0.2 mg/min 5-MeO-DMT; DRUG: 0.4 mg/min 5-MeO-DMT; DRUG: 0.6 mg/min 5-MeO-DMT; DRUG: 0.8 mg/min 5-MeO-DMT; DRUG: Placebo | Registry start date type: ESTIMATED (2026-03-31).
NCT06810765 Phase 2 Stopped updated Aug 22, 2025
- Condition
- PTSD - Post Traumatic Stress Disorder; Cognitive Dysfunction; Brain Trauma; Brain Injuries
- Sponsor / institution
- Johns Hopkins University
- Start date
- —
Tracker note / source boundary
ClinicalTrials.gov manual QA on 2026-04-17 | Exact registry status: Withdrawn | Official title: Trifecta Research Study: Examining Hormone Replacement Therapy, Magnetic e-Resonance Therapy, Ibogaine, and 5-MeO-DMT in the Treatment of Posttraumatic Stress Disorder and Traumatic Brain Injury-related Cognitive Symptoms | Sponsor: Johns Hopkins University | Conditions: PTSD - Post Traumatic Stress Disorder; Cognitive Dysfunction; Brain Trauma; Brain Injuries | Interventions: Hormone Replacement Therapy (HRT); Magnetic Resonance Therapy (MeRT); ibogaine with magnesium treatment; 5-MeO-DMT | Study type: Interventional
NCT05870540 Phase 2 Completed updated Jul 17, 2025
- Condition
- Treatment Resistant Depression
- Sponsor / institution
- Beckley Psytech Limited
- Start date
- Sep 14, 2023
Tracker note / source boundary
ClinicalTrials.gov v2 verification on 2026-04-24 | Overall status: COMPLETED | Exact phase: PHASE2 | Lead sponsor: Beckley Psytech Limited | Conditions: Treatment Resistant Depression | Interventions: DRUG: BPL-003; DRUG: BPL-003 | Asset identity checked against atai/Beckley 2025-10-16 source: BPL-003 is intranasal mebufotenin (5-MeO-DMT) benzoate.
NCT05800860 Phase 2 Completed updated May 31, 2025
- Condition
- Treatment-resistant Depression
- Sponsor / institution
- GH Research Ireland Limited
- Start date
- May 24, 2023
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 2 | Lead sponsor: GH Research Ireland Limited | Conditions: Treatment-resistant Depression
NCT06812221 Phase 1/2 Completed updated Apr 9, 2025
- Condition
- Mild Cognitive Impairment; Anxiety State; Depression Anxiety Disorder
- Sponsor / institution
- Biomind Labs Inc.
- Start date
- Dec 15, 2024
Tracker note / source boundary
ClinicalTrials.gov manual QA on 2026-04-17 | Status: Completed | Sponsor: Biomind Labs Inc. | Official title: A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Trial of Multiple Sublingual 5-MeO-DMT Microdoses for Reducing Anxiety and/or Depression in Patients With Mild Cognitive Impairment. | Condition: Mild Cognitive Impairment; Anxiety State; Depression Anxiety Disorder | Intervention: Sublingual 5-MeO-DMT microdoses plus psychiatric, cognitive, biochemical, and EEG assessments | Study type: Interventional
NCT06816667 Phase 1/2 Completed updated Mar 5, 2025
- Condition
- Healthy Volunteers
- Sponsor / institution
- Biomind Labs Inc.
- Start date
- Oct 21, 2024
Tracker note / source boundary
ClinicalTrials.gov manual QA on 2026-04-17 | Status: Completed | Sponsor: Biomind Labs Inc. | Official title: A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability and Efficacy of Multiple Sublingual Microdoses of 5-MeO-DMT in Reducing Symptoms of Depression and/or Anxiety. | Condition: Healthy Volunteers | Intervention: BMND08 sublingual 5-MeO-DMT formulation plus monitoring procedures | Study type: Interventional
NCT05839509 Phase 2 Stopped updated Feb 18, 2025
- Condition
- Bipolar II Disorder
- Sponsor / institution
- GH Research Ireland Limited
- Start date
- Apr 6, 2023
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: TERMINATED | Exact phase: Phase 2 | Lead sponsor: GH Research Ireland Limited | Conditions: Bipolar II Disorder
NCT05804708 Phase 2 Stopped updated Feb 18, 2025
- Condition
- Postpartum Depression, Postnatal Depression
- Sponsor / institution
- GH Research Ireland Limited
- Start date
- Mar 2, 2023
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: TERMINATED | Exact phase: Phase 2 | Lead sponsor: GH Research Ireland Limited | Conditions: Postpartum Depression; Postnatal Depression
NCT06511947 Phase 1 Recruiting updated Aug 7, 2024
- Condition
- Healthy Volunteers
- Sponsor / institution
- GH Research Ireland Limited
- Start date
- Aug 1, 2024
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: RECRUITING | Exact phase: Phase 1 | Lead sponsor: GH Research Ireland Limited | Conditions: Healthy Volunteers
NCT05698095 Phase 1 Completed updated Nov 30, 2023
- Condition
- Pharmacokinetics; Safety; Tolerability
- Sponsor / institution
- Usona Institute
- Start date
- Dec 27, 2022
Tracker note / source boundary
ClinicalTrials.gov manual QA on 2026-04-17 | Status: Completed | Sponsor: Usona Institute | Official title: A Phase 1, First-in-human, Double-blind, Placebo-controlled, Randomized, Single- and Multiple-ascending-dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) Administered by Intramuscular Injection in Healthy Subjects | Condition: Pharmacokinetics; Safety; Tolerability | Intervention: 5-methoxy-N,N-dimethyltryptamine succinate salt; Placebo | Study type: Interventional
NCT04640831 Phase 1 Completed updated Aug 15, 2023
- Condition
- Healthy Volunteers
- Sponsor / institution
- GH Research Ireland Limited
- Start date
- Mar 13, 2019
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: GH Research Ireland Limited | Conditions: Healthy Volunteers
NCT04698603 Phase 1 Completed updated Aug 15, 2023
- Condition
- Treatment Resistant Depression, Major Depressive Disorder, Depression
- Sponsor / institution
- GH Research Ireland Limited
- Start date
- Nov 12, 2019
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1, Phase 2 | Lead sponsor: GH Research Ireland Limited | Conditions: Treatment Resistant Depression; Major Depressive Disorder; Depression
NCT05032833 Phase 1 Completed updated Oct 12, 2022
- Condition
- Pharmacokinetics in Healthy Adults
- Sponsor / institution
- Beckley Psytech Limited
- Start date
- Sep 22, 2021
Tracker note / source boundary
ClinicalTrials.gov manual QA on 2026-04-17 | Status: Completed | Sponsor: Beckley Psytech Limited | Official title: A Double-Blind, Randomized, Phase 1, First-in-Human, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of Intranasal 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in Healthy Subjects | Condition: Pharmacokinetics in Healthy Adults | Intervention: 5-MeO-DMT; Placebo | Study type: Interventional
NCT05163691 Phase 1 Completed updated Dec 20, 2021
- Condition
- Healthy Volunteers
- Sponsor / institution
- GH Research Ireland Limited
- Start date
- Jun 21, 2021
Tracker note / source boundary
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1 | Lead sponsor: GH Research Ireland Limited | Conditions: Healthy Volunteers
Related updates
May 12, 2026 Last checked 2026-05-16 UTC Trial Update Company
Claim boundary.company-reported pipeline/capitalization and Phase 3-design tracker only; not approval, label, reimbursement, access, independent efficacy/safety confirmation, or proof that planned Phase 3 studies will start/succeed. Keep BPL-003, VLS-01, and EMP-01 separate from unrelated CNPV/company-primary-pending items.
AtaiBeckley company release says BPL-003 Phase 3 ReConnection remains on track for Q2 2026, with ReConnection-1 ~350 and ReConnection-2 ~230, MADRS Week 4 primary, and 52-week OLE; VLS-01 Phase 2 Elumina topline is anticipated Q4 2026; EMP-01 oral R-MDMA Phase 2a in SAD showed company-described convergent improvements; cash/securities were $209.9M with runway into 2029.
Source/tracker note
Last checked 2026-05-16 UTC. Claim boundary: company-reported pipeline/capitalization and Phase 3-design tracker only; not approval, label, reimbursement, access, independent efficacy/safety confirmation, or proof that planned Phase 3 studies will start/succeed. Keep BPL-003, VLS-01, and EMP-01 separate from unrelated CNPV/company-primary-pending items.
Conditions touched
Bipolar II DisorderHealthy AdultHealthy ParticipantsHealthy VolunteersMild Cognitive Impairment; Anxiety State; Depression Anxiety DisorderPharmacokinetics in Healthy AdultsPharmacokinetics; Safety; TolerabilityPostpartum Depression, Postnatal DepressionPTSD - Post Traumatic Stress Disorder; Cognitive Dysfunction; Brain Trauma; Brain InjuriesTreatment Resistant DepressionTreatment Resistant Depression, Major Depressive Disorder, DepressionTreatment-resistant Depression